Related by context. All words. (Click for frequent words.) 75 Prospective Randomized 74 RE LY ® 74 Acute Ischemic Stroke 74 Randomised 74 Infarct 73 EURIDIS 73 Acute Myocardial Infarction 72 Randomized Clinical Trial 72 Pivotal Trial 72 Fondaparinux 72 multicentre randomized 71 Randomized Study 71 RE LY 71 Controlled Trial 71 Thrombolysis 71 Phase III Clinical Trial 71 Double Blind Randomized 71 Ranolazine 71 Prospective Multicenter 71 Clinical Outcome 71 Left Ventricular 71 Carotid Stenting 71 Study Evaluating 70 Catheter Ablation 70 multicenter randomized controlled 70 unfractionated heparin UFH 70 Stent Restenosis 70 Oral Fingolimod 70 Clinical Trial Evaluating 70 TAXUS ATLAS 70 Prospective Randomized Trial 70 NSABP B 70 Multicenter 70 Clinical Evaluation 70 Abciximab 70 Myocardial Infarction Study 70 CHAMPION PCI 70 Long Term Efficacy 70 Meets Primary Endpoint 70 Patency 70 Percutaneous Tibial Nerve Stimulation 70 Coronary Artery Bypass Graft 69 prospective randomized multicenter 69 Platelet Inhibition 69 Severe Sepsis 69 Relapsing Multiple Sclerosis 69 Percutaneous Coronary Intervention 69 Treated Patients 69 STRIDE PD 69 Arimidex Tamoxifen Alone 69 Remission Maintenance 69 Eluting Stent 69 Subgroup Analysis 69 Unfractionated Heparin 69 Radiofrequency Ablation 69 Bivalirudin 69 EVEREST II 69 Controlled Study 69 Pooled Analysis 69 Carotid Revascularization Endarterectomy vs. 69 Prolongs Survival 69 MEND CABG 69 phase IIIb 69 Pulmonary Arterial Hypertension 69 Autologous Stem Cell Transplantation 69 Pharmacokinetic Study 69 Stenting 69 Tiotropium 68 Placebo Controlled Trial 68 Acute Coronary Syndromes 68 Randomized Double Blind 68 Chronic Heart Failure 68 fosbretabulin 68 COPERNICUS 68 prospective multicenter randomized 68 Patients Treated With 68 Acute Decompensated Heart Failure 68 Plaque Psoriasis 68 Patients Undergoing 68 MADIT II 68 Patient Outcomes 68 Intravitreal 68 Randomized Phase II 68 multicenter prospective 68 Overactive Bladder 68 Phase III Trial 68 multicenter multinational 68 Carotid 68 Pivotal Study 68 Efficacy Trial 68 JAK Inhibitor 68 Phase Ib Clinical Trial 68 Demonstrates Significant 68 Embolic Protection Device 68 Randomized Double blind 68 Randomized Double Blind Placebo 68 Pegylated Liposomal Doxorubicin 68 Sirolimus Eluting Stent 68 prospective multicenter 68 Phase IIIb 68 Patients Treated 68 Nebulized 68 Peripheral Arterial 68 Phase IIb Trial 68 Phase IIb Clinical Trial 68 Demonstrates Sustained 68 Unstable Angina 68 NDA Submission 68 Renal Cell Carcinoma 68 STENT 67 Novel Oral 67 multicenter randomized clinical 67 transcranial Doppler ultrasound 67 Sipuleucel T 67 RE MODEL 67 Neoadjuvant 67 Bosutinib 67 Adjuvant Therapy 67 Observational Study 67 multicenter randomized placebo controlled 67 Diabetic Nephropathy 67 Cilostazol 67 RELIANT 67 Ziprasidone 67 Phase 2b Study 67 Refractory Angina 67 Valsartan 67 ONTARGET 67 eluting stent 67 Monotherapy 67 Phase 2b Clinical Trial 67 CLARITY TIMI 67 Risk Stratification 67 Multicenter Randomized 67 Recurrent Stroke 67 Infarction 67 Pivotal Phase III 67 Randomized Trials 67 Completes Enrollment 67 Val HeFT 67 CALGB # [002] 67 SPIRIT FIRST 67 Randomized Controlled Trial 67 Metastatic Prostate Cancer 67 Diabetic Neuropathy 67 Randomized controlled 67 Antihypertensive 67 Is Well Tolerated 67 Intervention Trial 67 multicentre randomized double 67 Randomized Clinical Trials 67 randomized multicenter 67 Nesiritide 67 Parathyroid Hormone 67 Confirms Efficacy 67 Dose Ranging Study 67 Aggressive Reduction 67 Antiviral Activity 67 Venous Thromboembolism 67 Hepatocellular Carcinoma 67 ST Segment Elevation 67 Improves Outcomes 67 RENAL 67 Heart Failure Patients 67 Myocardial Infarction 67 Ischemic Stroke 67 Pivotal Phase 67 Valve Replacement 67 Rheumatoid Arthritis Patients 67 FDA Approvals 67 Meta Analysis 67 Schizophrenia Treatment 66 Randomized Controlled 66 Localized Prostate Cancer 66 Aggressive Drug Evaluation 66 First Patient Dosed 66 Paroxysmal Atrial Fibrillation 66 NAVISTAR R 66 Trial Evaluating 66 Bare Metal Stent 66 PRECISE 66 Degarelix 66 Decompensated Heart Failure 66 Moxifloxacin 66 Cypher Sirolimus 66 TM Drug Eluting 66 Glatiramer Acetate 66 TMC# C# 66 Clinical Trial Results 66 prospective multicentre 66 First Patient Enrolled 66 Gastric Cancer 66 somatostatin analog 66 Initiated Phase 66 Advanced Melanoma 66 Achieves Primary Endpoint 66 Restenosis 66 Single Dose 66 TRANSFORMS 66 PRoFESS 66 HCV SPRINT 66 Pivotal Clinical Trial 66 MIVI III 66 Randomized Controlled Trials 66 Bare Metal Stents 66 Improves Survival 66 Stent Thrombosis 66 Intervention Effectiveness 66 multicenter randomized double 66 Intravascular 66 Elderly Patients 66 Betaferon R 66 placebo controlled Phase III 66 Diabetic Foot Ulcer 66 Myocardial Ischemia 66 Adjuvant Chemotherapy 66 Intracranial 66 Adjuvant Treatment 66 Peginterferon 66 Demonstrates Efficacy 66 Phase 2a Clinical Trial 66 Study Demonstrates 66 Enoxaparin 66 MIST II 66 randomized multicenter trial 66 Metabolic Efficiency 66 Symptom Relief 66 Vertebral Fracture 66 REALITY Trial 66 NCT# ClinicalTrials.gov 66 vs. Angiography 66 multicenter randomized 66 DAPT 66 Tumor Response 66 Combination Treatment 66 Secondary Hyperparathyroidism 66 Clinical Efficacy 66 Left Ventricular Dysfunction 66 multicenter phase 66 Hypertensive Patients 66 Acute Myocardial 66 carotid artery stenting CAS 66 randomized controlled Phase 66 relapsing multiple sclerosis 66 Immunosuppression 66 Ischemic 66 Newly Diagnosed Multiple Myeloma 66 Phase III Clinical Trials 66 Relapsed Multiple Myeloma 66 Combination REOLYSIN R 66 Tyrosine Kinase Inhibitor 66 Echocardiographic 66 renal artery stenting 66 Patients Receiving 66 Zemplar Capsules 66 Renal Artery 66 Lung Cancer Trial 66 randomized Phase IIb 66 Inflammatory Pain 65 Stent Implantation 65 pharmacokinetic PK 65 Drug Eluting Stents 65 Biphasic 65 Shows Efficacy 65 Statistically Significant 65 Phase 2b Trial 65 Septic Shock 65 Diabetic Patients 65 Hemodialysis Patients 65 Randomized Phase 65 Phase Ib II 65 ACE Inhibitor 65 Carotid Artery Stenting 65 prospective nonrandomized 65 Multicenter Phase 65 GW# [003] 65 Hormone Refractory Prostate Cancer 65 Insulin Glargine 65 Confirmatory Phase 65 Hormone Receptor Positive 65 Nilotinib 65 Heart Failure Trial 65 ASTEROID 65 multicenter Phase III 65 Sirolimus eluting 65 Neoadjuvant Chemotherapy 65 Rosuvastatin 65 TO AVOID PREGNANCY WHILE 65 Initiate Clinical Trial 65 PROTEGE 65 Allogeneic 65 Renal Function 65 ENGAGE AF TIMI 65 trials RCTs 65 Phase IIIb clinical 65 Ancrod 65 Phase III Pivotal 65 Renal Cancer 65 Cardiovascular Outcomes 65 Aortic Stenosis 65 Prostate AdenoCarcinoma Treatment 65 Castration Resistant Prostate Cancer 65 Granted Orphan Drug 65 EchoCRT 65 Mycophenolate Mofetil 65 Tipranavir 65 II Clinical Trial 65 Surgical Treatment 65 cinacalcet 65 Study Showed 65 Resection 65 See CLINICAL PHARMACOLOGY 65 HCV RESPOND 2 65 Endarterectomy 65 relapsed MM 65 Demonstrate Significant 65 Spine Patient Outcomes 65 Severe Asthma 65 candesartan cilexetil 65 Efficacy Study 65 Dupuytren Contracture 65 First Patient Treated 65 Bone Mineral Density 65 vernakalant hydrochloride 65 Laryngeal Cancer 65 Demonstrated Significant 65 ST Elevation Myocardial 65 Multicenter Trial 65 registrational Phase 65 Combination Therapy 65 Dose Ranging 65 NEVO 65 recurrent glioblastoma multiforme 65 TAXUS Stent 65 nonrandomized 65 Edge STudy 65 Phase III Pivotal Trial 65 Stenting Trial CREST 65 Intracoronary 65 abacavir Ziagen 65 Drug Eluting 65 ExTRACT TIMI 65 everolimus eluting stent 65 Cardiogenic Shock 65 Lung Injury 65 Non inferiority 65 Total Knee Arthroplasty 65 Fracture Risk 65 prospective randomized controlled 65 Advanced Renal Cell 65 blinded randomized 65 Relapsing Remitting Multiple Sclerosis 65 double blinded randomized 65 Dose Response 65 IN PATIENTS WITH 65 Double Blind Placebo 65 Aortic Valve 65 Advanced Colorectal Cancer 65 ENDEAVOR III 65 multicentre randomized controlled 65 Treating Chronic 65 TAXUS VI 65 Multicenter Randomized Double 65 ritonavir boosted 65 Cholesterol Levels SPARCL 65 Non Responders 65 ACTEMRA TM 65 Endeavor Drug Eluting 65 By JENNIFER LEARN 65 prospectively defined 65 Eluting Coronary Stent System 65 CIMZIA TM certolizumab pegol 65 Appears Safe 64 Coronary Angiography 64 APTIVUS 64 Randomized Phase III 64 Peginterferon Alfa 2a 64 Menstrual Pain 64 Phase Ib clinical 64 Follicular Lymphoma 64 Pafuramidine 64 Uterine Cancer 64 phase IIb clinical 64 icatibant 64 Long Lesion 64 Demonstrates Positive 64 Antigen Specific 64 Fulvestrant 64 Platinol ® 64 Adalimumab 64 Events MACE 64 #:# randomization 64 CCX# B 64 Stent Coating 64 Microplasmin 64 Adenoma Prevention 64 Gastrointestinal Stromal Tumors 64 Prevent Stroke 64 Aneurysm Repair 64 Insulin Therapy 64 PREVAIL 64 secondary efficacy endpoint 64 AIR2 Trial 64 Versus Placebo 64 everolimus eluting stents 64 CARE HF 64 GISSI 64 GOUT 64 Dose Escalation 64 Shows Promising 64 Stenting Trial 64 Embolic Protection 64 Recurrent Prostate Cancer 64 pharmacokinetic PK study 64 PERSEUS 64 Recurrent Glioblastoma 64 ENDEAVOR II 64 Interagency Registry 64 Trandolapril 64 Carotid Endarterectomy 64 Clinical Antipsychotic Trials 64 multicenter clinical 64 Anticoagulation 64 epoetin alpha 64 ARIXTRA 64 Adjunctive Therapy 64 AIM HIGH 64 Renal Cell Carcinoma RCC 64 prospective randomized placebo 64 Investigational Treatment 64 Systemic Sclerosis 64 IMPACT DCM 64 CLINICAL PHARMACOLOGY 64 Raloxifene Evaluation MORE 64 Stable Angina 64 Bone Metastases 64 MR Angiography 64 sipuleucel T 64 Non Alcoholic Steatohepatitis 64 ribavirin RBV 64 Mg Usa 64 Balloon Angioplasty 64 Endurant 64 Angiographic 64 Adjunctive 64 biliary tract cancer 64 Biolimus A9 64 BRIM2 64 Aliskiren 64 Critical Limb Ischemia CLI 64 Pemetrexed 64 multicenter placebo controlled 64 Transcatheter 64 Antithrombin 64 PHASE III 64 Hospitalized Patients 64 Hemodynamic 64 Patients Enrolled 64 Invasive Fungal Infections 64 multicenter Phase II 64 BRIM3 64 Endovascular Treatment 64 Estrogen Therapy 64 Replacement Therapy 64 Fracture Intervention Trial 64 Teriparatide 64 Anti Platelet 64 Oral Calcitonin 64 multicentre 64 MADIT 64 Xelox 64 Knee Osteoarthritis 64 Lenalidomide 64 melphalan prednisone 64 EXPAREL ™ 64 CABG Surgery 64 CT Angiography 64 Chronic Hepatitis C 64 DEFER 64 Antiplatelet 64 Randomized Trial 64 Candesartan 64 Inflammatory Markers 64 Natalizumab 64 placebo controlled clinical 64 Placebo Controlled 64 MERLIN TIMI 64 assessing T DM1 64 liposome injection 64 Vascugel ® 64 Cardiac Resynchronization Therapy 64 Elagolix 64 HDL Selective Delipidation 64 Dual Antiplatelet Therapy 64 Venous Thrombosis 64 Unresectable 64 BCIRG 64 Sandostatin R 64 Significantly Reduces 64 Estrogen Receptor 64 ACTIVE W 64 Cardiovascular Events 64 Left Atrial 64 Sevelamer 64 Inhaled Corticosteroids 64 Eluting 64 Recombinant Human 64 AVOREN 64 vapreotide acetate 64 Randomized 64 sirolimus eluting stent 64 Protease Inhibitor 64 ACUITY trial 64 Reperfusion Injury 64 Metastatic Renal Cell Carcinoma 64 Initiate Phase 64 Investigational Drug 64 Clostridium difficile Infection 64 Successfully Completes Phase 64 Cloretazine ® 64 Phase IIB 64 Adverse Event 64 TRITON TIMI 64 C1 Inhibitor 64 Carotid Stent 64 TAXUS Express2 64 Decitabine 64 Sustained Efficacy 64 Thrombin 64 Interferon Gamma 64 double blinded placebo 64 NICE SUGAR 64 certolizumab 64 Resynchronization 64 ENDEAVOR IV 64 Sorafenib HCC Assessment 64 miconazole Lauriad ® 64 R# #mg BID 64 thrombus aspiration 64 Outpatient Setting 64 PFO migraine 64 Investigational Compound 64 Intracranial Aneurysms 64 Posaconazole 64 Recurrent Breast Cancer 64 Chronic Renal Failure 64 Pharmacodynamics 64 Phase III ThermoDox 64 Celecoxib APC trial 64 Fractional Flow Reserve 64 XIENCE V PROMUS Stent 64 Aortic Dissection 64 Hepatitis C Genotype 64 Embolization 64 Endovascular Valve Edge 64 Placebo controlled 64 CLARITY study 64 MGd 64 Amrubicin 64 Myelodysplastic Syndrome MDS 64 PROVENGE ® 64 Current Controlled Trials 64 R lenalidomide 64 Olmesartan 64 Antitumor Activity 64 Cardiotoxicity 64 Myoblast 63 Fungal Infections 63 Data Suggest 63 Drug Eluting Stent System 63 Molecular Weight Heparin 63 beta 1a 63 recurrent GBM 63 ID NCT# 63 Long Term Outcomes 63 Treatment Naive 63 Clinical Relevance 63 Diastolic Heart Failure 63 Breast Cancer Recurrence 63 Androxal TM 63 Antiplatelet Therapy 63 multicentre prospective 63 sirolimus eluting stents 63 Endoprosthesis 63 Monitoring ABPM 63 Improve Survival 63 PEGINTRON TM 63 TM Everolimus Eluting 63 Benign Prostatic Hyperplasia 63 ENESTnd 63 subanalysis 63 Progenitor Cells 63 Safinamide 63 Clopidogrel 63 Telmisartan 63 Vascular Grafts 63 demonstrated clinically meaningful 63 antiarrhythmic drug 63 Antitumor 63 treat benign prostatic 63 Artery Disease 63 Pharmacokinetic 63 Patient Enrollment 63 CALERIE 63 Radical Prostatectomy 63 Post Operative 63 Phase III randomized 63 Hepatitis C Antiviral 63 Pegylated Interferon 63 See WARNINGS 63 Therapy Evaluation 63 ACOMPLIA R 63 sirolimus eluting 63 ATAC Arimidex Tamoxifen Alone 63 Aflibercept 63 Dyloject TM 63 Therapeutic Efficacy 63 Myocardial Perfusion Imaging 63 dual endothelin receptor antagonist 63 Acute Stroke 63 Medidur TM FA 63 Cardiac Resynchronization 63 complement inhibitor eculizumab 63 Asthma Intervention 63 PROTECT AF 63 Completes Patient Enrollment 63 Novel Inhibitor 63 GORE TAG Device 63 Pertuzumab 63 Medullary Thyroid Cancer 63 Files IND 63 Cardiopulmonary Bypass 63 VADT 63 ARIXTRA R 63 MEND CABG II 63 AA Amyloidosis 63 Thrombectomy 63 ARCOXIA 63 Hepatotoxicity 63 Initiates Clinical Trial 63 Kidney Transplant Patients 63 Renal Insufficiency 63 Ischemia 63 Drug Candidate 63 Invasive Breast Cancer 63 Node Positive 63 Oral Mucositis 63 Reduces Mortality 63 SANTE 63 fludarabine cyclophosphamide 63 Antiviral Therapy 63 Clinical Outcomes Utilizing Revascularization 63 Vertebroplasty 63 paclitaxel poliglumex 63 Anticancer Drug 63 Proven Effective 63 Phase 1a clinical 63 Immunomedics Announces 63 Acute Heart Failure 63 PRIALT 63 Significantly Improved 63 Atypical Hemolytic Uremic Syndrome 63 Chronic Sinusitis 63 CIMZIA ™ 63 direct thrombin inhibitors 63 RECORD1 63 Pharmacokinetics PK 63 Bucindolol 63 CIMZIA TM 63 ROCKET AF 63 Retinal Vein Occlusion 63 BAL# [002] 63 Ambulatory Blood Pressure 63 label multicenter 63 randomized blinded 63 Bioequivalence 63 Multicentre 63 Temsirolimus 63 CORD II 63 Medoxomil 63 number NCT# ClinicalTrials.gov 63 6R BH4 63 mITT population 63 noninferior 63 ILLUSTRATE 63 pegylated interferon alfa 2b 63 Advanced Pancreatic Cancer 63 Colorectal Cancer Patients 63 Levels Linked 63 riociguat 63 lexidronam injection 63 Simulect 63 ADMIRE HF 63 induced macular edema 63 Coronary Revascularization 63 Phase IIA 63 morphometric vertebral fractures 63 VNP#M 63 Naive Patients 63 Acute Coronary Syndrome 63 Thrombotic 63 ONTARGET R 63 Reperfusion 63 azilsartan medoxomil 63 Dasatinib 63 salmeterol fluticasone 63 Prognostic Value 63 Adult Stem Cell Therapy 63 undergoing elective percutaneous 63 controlled multicenter 63 Functional Dyspepsia 63 venous thromboembolic disease 63 Cardiomyocytes 63 Hypertrophy 63 Advanced Prostate Cancer 63 Lupus Drug 63 Blood Pressure Reduction 63 Elitek 63 Paclitaxel Eluting 63 Obese Patients 63 randomized controlled clinical 63 phase IIa clinical 63 Brain Metastases 63 ORENCIA ® 63 Metastatic Colorectal Cancer 63 PERSEUS clinical program 63 Significantly Improves 63 randomized controlled multicenter 63 doxorubicin docetaxel 63 Calcium Acetate 63 Neuroprotection 63 PEG IFN 63 acute peripheral arterial 63 Potent Inhibitor 63 Pioglitazone 63 IMPACT IMmunotherapy 63 Interferon Alfa 63 Teva Provides Update 63 Aortic Valve Replacement 63 Anti Tumor Activity 63 Cyclophosphamide 63 sorafenib Nexavar 63 Commences Phase 63 clevidipine 63 Thromboembolism 63 LUMINATE 63 CALGB 63 Cleviprex TM clevidipine 63 Platelet Function 63 Ozarelix 63 J Am Coll 63 Coagulation 63 Inhaled Nitric Oxide 63 MAGE A3 ASCI 63 Minimally Invasive Treatment 63 evaluating tivozanib 63 SUTENT ® 63 Depressive Symptoms 63 Plus Ribavirin 63 achieved CCyR 63 Topline Results 63 Catheter Associated 63 Bepreve TM 63 Inhalation Solution 63 rt PA 63 Epoetin 63 BENICAR 63 Stent Graft 63 Rilonacept 63 Fixed Dose 63 Intervention Effectiveness CATIE 63 Pharmacodynamic 62 Percutaneous Transluminal Coronary Angioplasty 62 Lipid Lowering 62 Metastatic Melanoma 62 Oral Insulin 62 Related Mortality 62 Prophylactic Treatment 62 Cardiopulmonary bypass 62 randomized Phase III 62 TLUS 62 prospectively stratified 62 XIENCE V Everolimus Eluting 62 ARCALYST ® rilonacept 62 Therapy Reduces 62 ASSERT 62 sargramostim 62 Systolic Blood Pressure 62 Hsp# Inhibitor 62 Statin Therapy 62 Thrombus 62 Intracerebral Hemorrhage 62 Efficacy Results 62 Shows Statistically Significant 62 Chemoradiation 62 Renal Anemia 62 Dabigatran 62 estramustine 62 Orally Active 62 MEVACOR 62 Tigecycline 62 STARFlex R 62 HER2 Positive Breast Cancer 62 Skeletal Muscle 62 Diabetic Macular Edema 62 Ferinject R 62 Virologic 62 EINSTEIN DVT 62 PROCRIT R 62 prospective observational 62 Clinical Trial Data 62 Liposomal 62 Coronary Artery Bypass Grafting 62 FEMALES SHOULD BE ADVISED 62 Ambrisentan 62 Breast Density 62 GORE VIABAHN Endoprosthesis 62 Vimpat R 62 Epoetin Alfa 62 HDAC Inhibitor 62 Demonstrates Potent 62 Spectrum Pharmaceuticals Announces 62 β blockers 62 Prognostic Significance 62 Dabigatran etexilate 62 Daclizumab 62 Bioavailability 62 EOquin TM 62 Initiates Phase II 62 zotarolimus eluting stent 62 Disease Progression 62 BENICAR HCT 62 Universal Flu Vaccine 62 uricase 62 Cinacalcet 62 Randomised Controlled Trial 62 Initiates Enrollment 62 Less Invasive 62 transurethral 62 colesevelam HCl 62 alfuzosin 62 Proves Effective 62 active comparator 62 Corticosteroid 62 RAVEL 62 Investigational Agent 62 Traficet EN 62 Percutaneous Coronary Interventions 62 Diamyd Medical Diamyd 62 Contrast Agent 62 VESTASYNC 62 PROMUS TM 62 Systematic Review 62 Pressure Monitoring 62 REVIVE Diabetes 62 CentriMag 62 Embolic 62 echocardiographic parameters 62 #-# Full Text 62 Shows Promise Against 62 Tacrolimus 62 Pirfenidone 62 ECASS 62 Fibrin Pad 62 Balloon Catheter 62 Left Atrial Appendage 62 catheter occlusion 62 paclitaxel eluting stents 62 Scandinavian Simvastatin Survival 62 Radiofrequency Ablation RFA 62 ANCHOR trial 62 PICSO ® 62 Phase IIa Clinical Trial 62 pain palliation 62 Multicenter Study 62 BARACLUDE R 62 Predict Risk 62 Randomized Placebo Controlled 62 Preclinical Study 62 Targeted Therapy 62 Drug Eluting Coronary Stent 62 IND Application 62 liposomal doxorubicin 62 ALN HPN 62 Novel Therapeutic 62 Placebo Controlled Study 62 Cryoablation 62 Endovascular System 62 Systemic Delivery 62 Phase III psoriasis 62 interferon gamma 1b 62 Ondansetron Injection USP 62 HALTS 62 Alfimeprase 62 prucalopride 62 Previously Treated 62 Phase IIb III 62 rFSH 62 TREDAPTIVE 62 LUX Lung 62 Demonstrates Statistically Significant 62 Benign Prostatic Hyperplasia BPH 62 tirofiban 62 primary percutaneous coronary 62 Initiates Clinical 62 Fabry Disease 62 Free Survival PFS 62 Allergic Rhinitis 62 Phase III Psoriasis 62 unstable angina pectoris 62 plasma kallikrein inhibitor 62 NATRECOR R 62 Dalbavancin 62 Zoledronic Acid 62 Protease Inhibitors 62 Ischaemic 62 Myocardial Infarction TIMI 62 J Clin 62 Resistant Hypertension 62 prospective multicenter study 62 Cypher Stent 62 Treprostinil 62 alfa 2a 62 CRMD# 62 Osteoarthritis Patients 62 Drug Eluting Stent 62 Contrast Agents 62 CAMMS# 62 Montelukast 62 Sirolimus eluting Coronary Stent 62 RhuDex 62 Neovascular Age Related Macular 62 Self Expanding Stent 62 Phase III HEAT 62 STOP AF 62 OPT CHF 62 placebo controlled randomized 62 Intra Arterial 62 ATACAND 62 Coronary Arteries 62 Investigational Device 62 Phase III multicenter 62 Eur J 62 rilonacept 62 SPIRIT IV 62 Hypercholesterolemia 62 RELIANT Trial 62 Anticancer Agent 62 Microalbuminuria 62 Soft Tissue Sarcoma 62 Spinal Fusion 62 Occlusion 62 Complicated Skin 62 EmbraceAC 62 Reduced Incidence 62 phase IIb trial 62 Androgen Deprivation Therapy 62 PROMUS R 62 Phase #b/#a clinical 62 Predict Response 62 Phase 1b Clinical Trial 62 Initiates Phase 2b 62 Phase III AFFIRM 62 UNLOAD 62 Endeavor drug eluting 62 ancrod 62 Malignant Glioma 62 FDA APPROVES 62 liposomal formulation 62 HCV Protease Inhibitor 62 ADVANCE PD 62 phase Ib 62 Ventricular 62 BR.# 62 SPIRIT III 62 Primary endpoints 62 NATRECOR ® 62 lanthanum carbonate 62 Congestive Heart Failure 62 HORIZONS AMI 62 WallFlex Biliary RX 62 PROMUS Element Stent 62 Percutaneous 62 ARB telmisartan 62 Heparin Bioactive Surface 62 TAXUS IV 62 Novel Compound 62 Lupus Nephritis 62 landmark ATHENA trial 62 Coronary Artery Calcium 62 Optical Coherence Tomography 62 Treatment Naive Patients 62 Daptomycin 62 Myeloma Patients 62 Bevacizumab 62 ACCOMPLISH 62 Anticoagulant 62 MoxDuo TM IR 62 DUROS